The Food and Drug Administration (FDA) recently denied the pharmaceutical company Bayer’s request to increase the use of low dose aspirin in the prevention of heart attacks.
In 2003, Bayer requested the FDA to expand the recommendation for using aspirin for primary prevention. The American Heart Association also suggested in 2002 to use it for the primary prevention of patients that are at higher risk of cardiovascular disease.
Earlier in 1998, the FDA permitted labeling for aspirin and its related products in the secondary prevention of cardiovascular events. Secondary prevention means that these products can be used for individuals with a history of heart attack, coronary artery disease, and angina.
It also includes patients who have undergone revascularization treatments such as angioplasty or stent placement and coronary bypass surgery.
Aspirin helps prevent blood clots and decreases inflammation in the body, which makes it effective for cardiovascular disease. Risk factors associated to the use of Aspirin include allergy and gastrointestinal intolerance, and gastrointestinal and intracerebral bleeding.
The FDA denied Bayer’s request after a review over several years because the risks are higher than its benefits. However, the Food and Drug Administration noted that the recommendation might be expanded at a future date with further ongoing studies.
Baby aspirin is recommended in the secondary prevention for heart attacks at a dose of 81 milligrams per day. However, the use of this product should be started only after proper consultation with a physician. According to the best cardiologists in New York, individuals should consult with a cardiologist to evaluate the total cardiovascular risk.
In 2003, Bayer requested the FDA to expand the recommendation for using aspirin for primary prevention. The American Heart Association also suggested in 2002 to use it for the primary prevention of patients that are at higher risk of cardiovascular disease.
Earlier in 1998, the FDA permitted labeling for aspirin and its related products in the secondary prevention of cardiovascular events. Secondary prevention means that these products can be used for individuals with a history of heart attack, coronary artery disease, and angina.
It also includes patients who have undergone revascularization treatments such as angioplasty or stent placement and coronary bypass surgery.
Aspirin helps prevent blood clots and decreases inflammation in the body, which makes it effective for cardiovascular disease. Risk factors associated to the use of Aspirin include allergy and gastrointestinal intolerance, and gastrointestinal and intracerebral bleeding.
The FDA denied Bayer’s request after a review over several years because the risks are higher than its benefits. However, the Food and Drug Administration noted that the recommendation might be expanded at a future date with further ongoing studies.
Baby aspirin is recommended in the secondary prevention for heart attacks at a dose of 81 milligrams per day. However, the use of this product should be started only after proper consultation with a physician. According to the best cardiologists in New York, individuals should consult with a cardiologist to evaluate the total cardiovascular risk.
